Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1161 - A randomized phase 2 trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Targeted Therapy;  Immunotherapy

Tumour Site


Thomas Stinchcombe


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


T.E. Stinchcombe1, P.A. Janne2, X. Wang3, E.M. Bertino4, J.M. Weiss5, L. Bazhenova6, L. Gu3, C.J. Lau2, C.P. Paweletz2, A.J. Jaslowski7, G.J. Gerstner8, M.Q. Baggstrom9, S.L. Graziano10, J. Bearden, III11, E.E. Vokes12

Author affiliations

  • 1 Medical Oncology, Duke Cancer Center, 27710 - Durham/US
  • 2 Medical Oncology, Dana Farber Cancer Institute, Boston/US
  • 3 Department Of Biostatistics And Bioinformatics, Duke University, Durham/US
  • 4 Medical Oncology, The Ohio State University James Cancer Hospital, 43210 - Columbus/US
  • 5 Hematology/oncology, University of North Carolina at Chapel Hill, Chapel Hill/US
  • 6 Medicine, Moores UCSD Cancer Center, 92093 - La Jolla/US
  • 7 Medical Oncology, St. Mary's Hospital, 54303 - Green Bay/US
  • 8 Medical Oncology, Illinois CancerCare, P.C., Peoria/US
  • 9 Medical Oncology, Washington University School of Medicine, St. Louis/US
  • 10 Medical Oncology, SUNY Upstate Medical University, 13210 - Syracuse/US
  • 11 Medical Oncology, Palmetto Hematology Oncology Associates, Spartanburg/US
  • 12 Medical Oncology, The University of Chicago Medical Centre, 60637-1470 - Chicago/US

Abstract 1161


A retrospective subset analysis from a phase 3 trial, and preclinical data supported prospective study of elrotinib and bevacizumab in patients (pts) with EGFR mutant NSCLC.


Pts were required to have an EGFR exon 19 deletion or exon 21 L858R mutation based on local testing. Pts were assigned to erlotinib 150 mg daily (E) or erlotinib 150 mg daily and bevacizumab 15 mg/kg IV every 3 weeks (EB). The primary objective was progression-free survival (PFS); secondary objectives were objective response rate (ORR), and overall survival (OS). cfDNA samples were collected at baseline, at time of imaging, and disease progression. The study was designed to detect a hazard ratio (HR) of 0.667 in favor of EB, with a power of 81% at one-sided significance level of 0.20; under exponential hazards. HR corresponds to an improvement in median PFS from 10 to 15 months.


From 11/2012 to 8/2016 88 pts were enrolled. The median age was 63 years (range 31 to 84), the majority were women (70%), had a history of never smoking (55%), performance status (PS) of 1 (51%), and EGFR exon 19 deletion (67%). With a median follow-up of 23 months, 69 PFS events have been observed. A statistically significant difference in PFS in pts assigned to EB compared to E was not observed (HR of 0.87, 95 CI: 0.54-1.43; p = 0.59; median PFS 17.9 and 13.5 months, respectively). The ORR in the EB and E arms were 83% vs 81% (p = 1.0). 33 OS events have been observed. The OS analysis of pts assigned to EB compared to E revealed a HR of 1.54, 95% CI: 0.74-3.19, p = 0.25; median OS 29.9 months and not evaluable, respectively. Grade ≥ 3 adverse events (rate ≥ 10%) in the EB and E arms were: rash (26% and 18%), diarrhea (9% and 13%), hypertension (40% and 22%), and proteinuria (12% and 0%). In EB and E arms 23 and 21 pts received subsequent therapies; in the EB and E arms osimertinib was a subsequent therapy in 10 and 13 pts, respectively. cfDNA were available for 36/69 pts with progressive disease; exon 19 deletion or exon 21 L858R detected in 12 samples and T790M in 5 samples.


Treatment with EB compared to E did not result in a statistically significant improvement in PFS in pts with EGFR mutant NSCLC. OS data are immature. A review of subsequent therapies and additional cfDNA analyses are ongoing.

Clinical trial identification


Legal entity responsible for the study

Academic and Community Cancer Research United.



Editorial Acknowledgement


T.E. Stinchcombe: Advisory board related to immunotherapy: Genentech; Advisory board: AstraZeneca; Research funding to institution for clinical trials: Genentech/Roche and AstraZeneca. P.A. Janne: Consultant: BI, Pfizer, Roche/Genentech, Chugai, Ariad, AstraZeneca, Merrimack, Acea Bioscience; Research funding: Astellas, AstraZeneca, BI; Post-marketing royalties: Dana Farber Cancer Institute for intellectual property on EGFR mutations licensed to Lab Corp. E.M. Bertino: Advisory board: BI. E.E. Vokes: Consultant/advisory roles: AstraZeneca, Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.